OncoImmunin, Inc. is an established biotechnology company with a fascinating focus on developing unique and patented delivery technology for peptides and oligonucleotides. Founded in 1994, the company is based in the United States. With its patented technology, OncoImmunin is positioned to make significant strides in the biotechnology space.
The company’s novel approach to peptide and oligonucleotide delivery presents substantial potential for breakthroughs in the field of biotechnology. This technology could revolutionize the way these compounds are delivered and utilized, opening new possibilities in drug development and treatment methodologies.
Although there is no publicly available information about the last investment or the investors involved, OncoImmunin, Inc. clearly holds promise within the biotechnology sector. Its long-standing presence since 1994 indicates stability and resilience, while its focus on patented delivery technology suggests a commitment to innovation and advancement within the field.
There is no investment information
No recent news or press coverage available for OncoImmunin, Inc..
We care about your data, and we'd love to use cookies make your experience better.
